Compare Schlumberger NV (SLB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs TransMedics Group Inc — how do they compare? Schlumberger NV trades at $57.5 (market cap $84.67B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Schlumberger NV is far larger — about 28.2× TransMedics Group Inc's market cap, and Schlumberger NV pays a 2.07% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SLB | TMDX | |
|---|---|---|
Market Cap | $84.67B | $3.00B |
Sector | Energy | Technology |
52-Week High | $60.10 | $150.42 |
52-Week Low | $31.72 | $61.99 |
Enterprise Value | $93.40B | $3.39B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $57.10, down 0.71% on the day, with strong analyst support (85% buy ratings) and a $63.50 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a strategic $3.4 billion acquisition of Kelvion to expand into data center cooling technology. Revenue remains stable at $35.7 billion (2025) with solid profitability metrics including 8.53% net margin and 13.37% ROE.
The outlook remains positive with diversification into high-growth data center markets, though risks include oil price volatility and execution challenges from recent acquisitions. Current valuation at 27.85 P/E appears reasonable given growth initiatives, supporting a constructive view for long-term investors despite near-term market fluctuations.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
